Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT01772602 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The National Amyotrophic Lateral Sclerosis Registry

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv13
  2. Primary and study completion dates: Dec 2030 to Dec 2040v12
  3. Enrollment target: 17000 to 30000v11
  4. Re-verified, no change to tracked fieldsv10
  5. Primary and study completion dates: Dec 2025 to Dec 2030v9
Show 7 earlier versionsHide 7 earlier versions
  1. Primary and study completion dates: Dec 2022 to Dec 2025
    • Enrollment target: 16000 to 17000
    • Collaborators revised (2)
    v8
  2. Primary and study completion dates: Dec 2020 to Dec 2022
    • Enrollment target: 13000 to 16000
    • Study description expanded, about 16 words
    v7
  3. Collaborators revised (2)v6
  4. Re-verified, no change to tracked fieldsv5
  5. Enrollment target: 5000 to 13000
    • Primary and study completion dates: Dec 2013 to Dec 2020
    v4
  6. Study site revisedv3
  7. Enrollment target: 4884 to 5000
    • Secondary endpoints expanded, about 4 words
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this registry is to (A) better describe the incidence and prevalence of Amyotrophic Lateral Sclerosis (ALS) in the United States;(B) examine appropriate factors, such as environmental and occupational, that may be associated with the disease; (C) better outline key demographic factors (such as age, race or ethnicity, gender, and family history of individuals who are diagnosed with the disease) associated with the disease; and (D) better examine the connection between ALS and other motor neuron disorders that can be confused with ALS, misdiagnosed as ALS, and in some cases progress to ALS.
Trial Details
NCT Number NCT01772602
Lead Sponsor Centers for Disease Control and Prevention
Collaborators: US Department of Veterans Affairs, Centers for Medicare and Medicaid Services
Conditions
(from sponsor)		 Amyotrophic Lateral Sclerosis
Related terms Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Enrollment 30,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov